|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
Datamonitor, Sep 2004, Pages: 306
Introduction
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. We have Metastatic and HRPC Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what they require in the future.
Scope
Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US
Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects
A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC and the implementation of screening in Europe
Highlights
Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.
Reasons to Purchase
Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
Plan product development to fill prostate cancer market niches as defined by practicing physicians
Customers who bought this item also bought
Stakeholder Insight: Prostate Cancer Treatment in the USA
Treatment Algorithms 2001: Prostate Cancer
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Prostate Cancer Therapeutics - Global Strategic Business Report
Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Prostate Cancer Opinion Leader Forum, 2002
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 World Forecasts of Butadiene Rubber (BR) Export Supplies
|
|
|
|
